The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and ...

ABIVAX Société Anonyme's Obefazimod shows robust efficacy and differentiation in early Phase 3 trials. Click here to read why ...

The FDA has approved AbbVie’s supplemental new drug application for Rinvoq (upadacitinib) to treat inflammatory bowel disease ...

Good morning, and welcome to Johnson & Johnson's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded. [Operator Instructions] I will now turn the ...

Chapter has named Raymond K. Cross, Jr., M.D., MS, AGAF, FACG, Medical Director of The Center for Inflammatory Bowel and Colorectal Diseases, part of The Melissa L. Posner Institute ...

The FDA has approved an updated indication for upadacitinib (Rinvoq; AbbVie) in inflammatory bowel disease (IBD), allowing its use in adults with moderately to severely active ulcerative colitis or ...

The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.

St. Mary’s Health Care System and the Oconee County Chamber of Commerce held a ribbon-cutting ceremony Thursday, Sept. 18, to ...

Liver, kidney, heart and lung transplants could soon be a thing of the past as work begins on a ‘natural’ cell treatment ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAHtm (fezolinetant), its first-in-class, targeted, non-hormonal treatment for moderate to severe ...

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion ...

Johnson & Johnson (JNJ) stock is in focus after the company reported earnings and announced a spin-off of its orthopedics ...